Medical devices

Medical devices

Until the application of a new regulatory framework for the EU beginning from 26 May 2021, the regulatory framework in the EU for medical devices, active implantable medical devices (AIMDs), and in vitro diagnostic medical devices (IVDs) consisted of:

  1. Directive 93/42/EEC on medical devices

  2. Directive 90/385/EEC on active implantable medical devices

  3. Directive 98/79/EC on in vitro diagnostic medical devices

These MD Directives remain relevant to ‘legacy’ devices and those that were placed on the market before applicable deadlines for certain devices to transition to the new EU regulations. However, all devices must comply with certain increased obligations of compliance under the new EU medical devices regulatory regime. See Practice Note: An introduction to the regulation of medical devices—EU Directives regime.

In the UK, the MD Directives have been implemented via the Medical Devices Regulations 2002 (MDR 2002), SI 2002/618, which were issued under the Consumer Protection Act 1987. The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK competent authority responsible for supervision of medical device regulation. The end of the Brexit transition period

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest Life Sciences News

MHRA publishes blog post highlighting £1.4bn opportunity from medicines reclassification

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a blog post authored by Proprietary Association of Great Britain (PAGB) CEO, Michelle Riddalls OBE, outlining what PAGB describes as a £1.4bn opportunity to transform healthcare through expanded medicines reclassification. Riddalls argues that increasing switches from prescription-only (POM) to pharmacy (P) or general sales list (GSL) status could improve timely access to treatments for common conditions, strengthen self-care and ease pressure on primary care, with the MHRA describing reclassification as a practical way to broaden access to trusted medicines and enable safe self-management of minor conditions. She states that 74% of adults want more medicines available without a prescription, positioning consumer demand as a key driver of switch applications, and frames reclassification as a catalyst for a prevention-focused healthcare model that enhances the role of community pharmacists and supports wider public health goals. Referencing previous switches to over-the-counter (OTC) status, including Nurofen, Allevia and Calpol, as well as low-dose vaginal oestrogen products and Viagra, she highlights both market impact and social significance and calls for reform of the legal framework for certain injectable medicines, pointing to potential benefits in areas including weight management and emergency treatments. Riddalls states that a 5% reduction in NHS prescribing could save £1.4bn annually, with productivity gains of up to £18bn linked to improved OTC symptom management. PAGB adds that reclassification is one of the most practical and impactful opportunities to strengthen self-care and deliver the ambitions of the NHS 10 Year Plan, citing clear opportunity, strong public demand and persuasive supporting evidence.

View Life Sciences by content type :

Popular documents